The interaction of mannose binding lectin (MBL) with mannose containing glycopeptides and the resultant potential impact on invasive fungal infection

References

• Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005; 41: 1232–1239
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239–244
   PubMed Web of Science ®Google Scholar
• Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531–1534
   PubMed Web of Science ®Google Scholar
• Vasta GR, Quesenberry M, Ahmed H, O'Leary N. C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Dev Comp Immunol 1999; 23: 401–420
   PubMed Web of Science ®Google Scholar
• Lp W, Lau Y. Role of mannose-binding lectin in the innate defense against Candida albicans: Enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190: 632–640
   PubMed Web of Science ®Google Scholar
• Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003; 40: 423–429
   PubMed Web of Science ®Google Scholar
• Jack DL, Klein NJ, Malcolm WT. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180: 86–99
   PubMed Web of Science ®Google Scholar
• van de Wetering JK, van Golde LM, Batenburg JJ. Collectins: players of the innate immunie sysem. Eur J Biochem 2004; 271: 229–249
   Google Scholar
• Holmskov U, Thiel S, Jensenius DC. Collectins and ficolins: humoral lectins of the innate immune defence. Annu Rev Immunol 2003; 21: 547–578
   PubMed Web of Science ®Google Scholar
• Somma S, Gastaldo L, Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother 1984; 26: 917–923
   PubMed Web of Science ®Google Scholar
• Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract 2007; 61: 853–863
   PubMed Web of Science ®Google Scholar
• Candiani G, Abbondi M, Borgonovi M, Romanò G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179–192
   PubMed Web of Science ®Google Scholar
• Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8: 943–950
   PubMed Web of Science ®Google Scholar
• Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006; 193: 1589–1597
   PubMed Web of Science ®Google Scholar
• Mini-PROTEAN® 3 Cell, Instruction Manual. Catalog Numbers 165-3301 and 165-3302. Bio-Rad Laboratories, Inc., USA. Available from http://www.bio-rad.com/cmc_upload/ Literature/44432/4006157B.pdf.
   Google Scholar
• SilverSNAP Stain Kit II® Instruction Manual. Number 24612. Pierce Biotechnology, Inc., USA. Available from http://www.technochemical.com/ instruction/1478dh4.pdf.
   Google Scholar
• National Committee for Clinical Laboratory Standards (NCCLC). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. Wayne, Pa: NCCLS, 2002.
   Google Scholar
• Sanquin: Human Mannose binding lectin ELISA kit product information. Amsterdam, Sanquin Reagents, 2006
   Google Scholar
• Peetermans WE, Hoogeterp JJ, Hazekamp-van Dokkum AM, van den Broek P, Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869–1874
   PubMed Web of Science ®Google Scholar
• Candiani G, Abbondi M, Borgonovi M, Romanò G, Parenti F. J. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. Antimicrob Chemother 1999; 44: 179–192
   Web of Science ®Google Scholar
• Kaneko Y, Yanagihara K, Miyazaki Y, et al. Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice. Antimicrob Agents Chemother 2003; 47: 3694–3698
   PubMed Web of Science ®Google Scholar
• Ghiselli R, Cirioni O, Giacometti A, et al. Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections. J Surg Res 2008; 144: 74–81
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51: 1633–1642
   PubMed Web of Science ®Google Scholar
• Walport MJ. Advances in immunology: complement (First of Two Parts). N Eng J Med 2001; 344: 1058–1066
   PubMed Web of Science ®Google Scholar
• Hoffman JA, Kafatos FC, Janeway CA, Ezekowitz R. Phylogenetic perspectives innate immunity. Science 1999; 284: 1313–1318
   PubMed Web of Science ®Google Scholar
• Suankratay C, Mold C, Zhang Y, et al. Complement regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein. Clin Exp Immunol 1998; 113: 353–359
   PubMed Web of Science ®Google Scholar
• Hill AVS. Human genetics and infection mechanisms. Principles and Practice of Infectious Diseases5th edn, GL Mandell, JE Bennett, R Dolin. Churchill Livingstone, Philadelphia 2001; 39, 42
   Google Scholar
• Fraser IP, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998; 10: 363–372
   PubMed Web of Science ®Google Scholar
• Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med 2003; 31(Suppl. 1)S97–104
   Web of Science ®Google Scholar
• NatImmune MBL information memorandum: a novel protein replacement for immune therapy and prophylaxis. Retrieved October 10, 2005, from http://www.natimmune.com/.
   Google Scholar
• Miller ME, Seals J, Kaye R, Levitsky LC. A familial, plasma-associated defect of phagocytosis: A new case of recurrent bacterial infections. Lancet 1968; 11: 60–63
   Google Scholar
• Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001; 358: 614–618
   PubMed Web of Science ®Google Scholar
• Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33: 638–644
   PubMed Web of Science ®Google Scholar
• Valdimarsson H, Stefansson M, Vikingsdottir T, et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand J Immunol 1998; 48: 116–123
   PubMed Web of Science ®Google Scholar
• Garred P, Lanng S, Madsen HO, et al. Mannose-binding lectin therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 2002; 33: 201–207
   PubMed Web of Science ®Google Scholar
• Kahn SJ, Wleklinski M, Ezekowitz RA, et al. The major surface glycoprotein of Trypanosoma cruzi amastigotes are ligands of the human serum mannose-binding protein. Infect Immun 1996; 64: 2649–2656
   PubMed Web of Science ®Google Scholar
• Green PJ, Feizi T, Stoll MF, et al. Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Mol Biochem Parasitol 1994; 66: 319–328
   PubMed Web of Science ®Google Scholar
• Garred P, Madsen HO, Halberg P, et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2145–2152
   PubMed Web of Science ®Google Scholar
• Santos IK, Costa CH, Krieger H, et al. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect Immun 2001; 69: 5212–5215
   PubMed Web of Science ®Google Scholar
• Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency-revisited. Mol Immunol 2003; 40: 73–84
   PubMed Web of Science ®Google Scholar
• Giraldo PC, Babula O, Goncalves AK, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol. 2007; 109: 1123–1128
   PubMed Web of Science ®Google Scholar
• Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92: 43–47
   PubMed Web of Science ®Google Scholar
• Babula O, Lazdane G, Kroica J, et al. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40: 1258–1262
   PubMed Web of Science ®Google Scholar
• Madan T, Kaur S, Saxena S, et al. Role of collectins in innate immunity against aspergillosis. Med Mycol 2005; 43(Suppl. 1)S155–163
   Web of Science ®Google Scholar
• Granell M, Urbano-Ispizua A, Suarez B, et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006; 34: 1435–1441
   PubMed Web of Science ®Google Scholar
• Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the MBL pathway. J Immunol 2001; 67: 2861–2868
   Google Scholar
• Roos A, Bouwman LH, Munoz J, et al. Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 2003; 39: 655–668
   PubMed Web of Science ®Google Scholar
• Roos A, Garred P, Wildenberg ME, et al. Antibody-mediated activation of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol 2004; 34: 2589–2598
   PubMed Web of Science ®Google Scholar
• Selander B, Martensson U, Weintraub A, et al. Mannan-binding lectin activates C3 and the alternate pathway without involvement of C2. J Clin Invest 2006; 116: 1425–1434
   PubMed Web of Science ®Google Scholar
• Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nat Biotechnol 2006; 24: 1541–1549
   PubMed Web of Science ®Google Scholar
• Hiramoto F, Nomura N, Furumai T, Oki T, Igarashi Y. Apoptosis-like cell death of Saccharomyces cerevisiae induced by a mannose-binding antifungal antibiotic, pradimicin. J Antibiot 2003; 56: 768–72
   PubMed Web of Science ®Google Scholar